Vertex Pharmaceuticals

First reimbursement agreement in #Chile: Eligible people living with #CysticFibrosis now have reimbursed access to one of our #CysticFibrosis therapies.

Major update for the treatment of cystic fibrosis (CF) in the U.S.: The FDA has approved the label extension for our triple combination therapies, expanding availability of these medicines to ~95% of all people with CF in the U.S. Learn more: news.vrtx.com/news-releases/…

We’re excited to share positive topline results from the interim analysis of the RAINIER Phase 3 study of our investigational therapy for #IgANephropathy. Learn more: news.vrtx.com/news-releases/…

We’re pleased to share results from the Phase 4 study of our non‑opioid treatment for moderate‑to‑severe acute pain, presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting: news.vrtx.com/news-releases/…

Announcing a reimbursement agreement with the Italian Medicines Agency (AIFA) for access to our latest cystic fibrosis (CF) therapy for eligible patients 6 years and older and expanded access to two of our other medicines for eligible patients 2 years old and older.

Vertex is committed to the safety and security of all job seekers. If you receive suspicious recruitment messages or believe you have been targeted by a recruitment scam, do not respond or provide any information. Learn how to identify recruitment scams: vrtx.com/beware-recruit…

We have entered a new reimbursement agreement for our latest #CysticFibrosis (CF) therapy in #Bulgaria. This new agreement has enabled broad access for eligible people living with CF ages 6 years and older since Jan 5, 2026.

Extended reimbursement agreement with the Croatian health authorities: Since Dec 30, 2025, eligible children living with #CysticFibrosis ages 1 year and older have had broad access to some of our medicines.

We are pleased to share new data from multiple studies of our gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia at the 67th ASH Annual Meeting this weekend. Learn more: news.vrtx.com/news-releases/… #ASH25

Extended reimbursement agreement with the health authorities of #Slovakia: eligible people living with #CysticFibrosis ages 2 year and older will now have broad access to one of our medicines.

We're excited to share several advancements across our investigational programs for the potential treatment of IgA nephropathy (IgAN), APOL1-mediated kidney disease (AMKD) and autosomal dominant polycystic kidney disease (ADPKD). Learn more: investors.vrtx.com/news-releases/…

#Breaking: Today Health Canada granted marketing authorization for our fifth cystic fibrosis (CF) medicine.

We are proud to announce that our acute pain medicine has been recognized as a 2025 Breakthroughs Innovation Celebration winner by @PremierHA, a leading healthcare improvement company. Learn more: news.vrtx.com/news-releases/…

Today the European Commission approved our fifth cystic fibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

We are excited to share that data for our investigational stem cell-derived, fully differentiated islet cell therapy for #Type1Diabetes were published in @NEJM. Learn more: nejm.org

#Breaking: Today we announced updated data for our investigational islet cell therapy for the treatment of #Type1Diabetes. Learn more: news.vrtx.com/news-releases/…

@bgale9 Hi, if you'd like, someone can contact you directly to discuss this matter. Can you please direct message us with your email address and phone number?

@VertexPharma Can you please have the rep for North Dakota call me? I've talked to him but I can't find his card he gave me. We have some pharmacies who do not have Journavx on their formulary and need more info from the company before they will order it for patients.

#Breaking: The U.S. FDA approves our treatment for moderate-to-severe acute pain in adults. This is the first new class of pain medicine to be approved in over 20 years. Learn more: news.vrtx.com/news-releases/…

Extended reimbursement agreement with the health authorities of #Slovenia: eligible children living with #CysticFibrosis ages 1 year and older will now have broad access to some of our medicines.

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our fifth cystic fibrosis (CF) medicine. This is an important step towards our goal of treating all people living with CF.

Today the European Commission approved the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step towards our goal of treating all people with CF.